 DEVON, Pa., Oct. 08, 2021 GLOBE NEWSWIRE -- Zynerba Pharmaceuticals, Inc. Nasdaq: ZYNE, the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics AAP National Conference Exhibition, which will be held virtually from October 8-11, 2021. A copy of the poster titled, Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder ASD: An Open-Label Phase 2 Study BRIGHT ZYN2-CL-030, will be made available on the Zynerba corporate website starting today, October 8, 2021 at Additional meeting information can be found on the AAP website at aapexperience.org. 